Trial Profile
Autologous T Cells Redirected to GPC3 for Treating Patients With Advanced HCC
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Oct 2023
Price :
$35
*
At a glance
- Drugs GPC3-CAR-T (Primary) ; Cyclophosphamide; Fludarabine
- Indications Liver cancer
- Focus Adverse reactions; First in man
- 12 Oct 2023 According to a CARsgen media release, the results from this trial were published in the Cancer Communications.
- 12 Oct 2023 Results presented in the CARsgen Media Release.
- 05 May 2020 Results (n=13) of pooled analysis of two studies (NCT02395250 & NCT03146234) assessing feasibility and safety of CAR-GPC3 T-cell therapy in adult Chinese patients with advanced, published in the Clinical Cancer Research.